Recently, Teva Pharmaceuticals (NYSE:TEVA) lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals Court ruling.
However, with the Supreme Court's term running from October 2014 until July 2015, how will that impact the ability of generic drug makers to launch generic versions of Copaxone on May 24, 2014? In this segment from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass take a look at Teva's appeal process, and how likely it is that the Supreme Court will grant a stay until the litigation surrounding this patent is complete. David and Michael also look at which of the generic players stand to lose out if the patent is upheld, and just how seriously this could affect Teva if the patent is allowed to expire.
David Williamson owns shares of Amarin plc (ADR). Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.